For a newborn in the NICU with a suspected bloodstream infection, the clock is the enemy. The current diagnostic standard, a blood culture, can take two to five days to return a result. In that window, clinicians must make a high-stakes guess, often prescribing broad-spectrum antibiotics that may be ineffective or contribute to resistance. Melio, a Santa Clara-based biotech startup, is building a platform designed to collapse that timeline to under three hours, delivering a pathogen ID and resistance profile directly from a whole blood sample without the need for a culture [Melio, retrieved 2024].
The race against sepsis
Melio’s core bet is a hardware-plus-software system that integrates microfluidics, proprietary assays, and a machine learning engine. The process begins with a small blood sample, which is loaded into a cartridge and analyzed using a technique called digital DNA melting genomic profiling. This method generates a unique genomic signature for any pathogen present, which Melio’s algorithms then match against a reference library to identify the specific bacteria or fungus and flag known antimicrobial resistance markers [Perplexity Sonar Pro Brief, retrieved 2024]. The company claims its test can identify 99% of the most common pathogens, a critical capability for guiding precise, early treatment [Melio, retrieved 2024]. The platform is designed for near-to-care settings, aiming to move diagnostics from a centralized lab closer to the patient’s bedside.
A grant-driven path to the clinic
Founded in 2018, Melio has navigated the long, capital-intensive road of medical device development through non-dilutive funding and accelerator support. Its most significant validation to date is a $3.5 million seed-stage grant awarded in January 2025 by CARB-X, a global nonprofit partnership focused on accelerating antibacterial products to combat drug-resistant infections [CARB-X, January 2025]. This funding is earmarked for development work, specifically for the platform’s application in neonatal sepsis. The company has also been through programs with SOSV’s IndieBio and the UC San Diego Institute for the Global Entrepreneur, which typically provide early-stage capital and technical mentorship [SOSV, retrieved 2026] [IndieBio, retrieved 2026].
2025 Seed Grant | 3.5 | M USD
The competitive and regulatory landscape
Melio is entering a field with established players and high technical hurdles. Competitors like T2 Biosystems have commercialized rapid, culture-free diagnostic systems, but often for a more limited panel of pathogens. Melio’s differentiation rests on its claim of a universal, software-updatable test. As described by its backers, the platform aims to break the “one-pathogen, one-probe” paradigm, using a few universal probes and machine learning to deliver “pathogen testing at the speed of software” [SOSV, retrieved 2026]. This ambition, however, comes with significant challenges.
- Clinical validation. The product is still in development and not yet commercialized [Perplexity Sonar Pro Brief, retrieved 2024]. Moving from promising lab data to a clinically validated, FDA-cleared device is a multi-year process requiring rigorous trials to prove safety and efficacy.
- Commercial execution. Successfully deploying a new hardware platform in hospital settings involves navigating complex procurement cycles, training clinical staff, and integrating with existing lab workflows.
- Market education. Convincing hospitals to adopt a new, paradigm-shifting diagnostic will require demonstrating not just technical superiority, but also a clear return on investment through improved patient outcomes and reduced antibiotic costs.
The company’s focus on neonatal sepsis, while addressing a dire need, also represents a strategically narrow initial market. Success there could provide the clinical proof point needed to expand into broader adult sepsis and bloodstream infection diagnostics.
The standard of care today
For clinicians treating suspected sepsis, especially in vulnerable populations like neonates, the current pathway is fraught with delay and uncertainty. A blood sample is drawn and placed in a culture bottle, where it is incubated for 24-48 hours or longer to allow any bacteria to grow. Only after a culture turns positive can further testing identify the specific pathogen and its antibiotic susceptibility. This lag forces a reliance on empiric therapy,powerful, broad-spectrum antibiotics administered in hope they will work. This approach contributes directly to the global crisis of antimicrobial resistance and can be tragically ineffective if the infection is caused by a drug-resistant organism. Melio’s entire proposition is to replace this days-long guessing game with a hours-long answer, a shift that could fundamentally alter the treatment arc for a patient with sepsis.
Sources
- [Melio, retrieved 2024] Rapid, Comprehensive Bloodborne Pathogen Testing | https://melio.tech/
- [CARB-X, January 2025] CARB-X is funding Melio to develop a rapid diagnostic for neonatal sepsis | https://carb-x.org/
- [SOSV, retrieved 2026] Melio company profile | https://sosv.com/
- [IndieBio, retrieved 2026] Melio company profile | https://indiebio.co/